Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of durvalumab with olaparib with or without bevacizumab in advanced solid tumors
MOH_2018-12-17_004817Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab, olaparib and bevacizumab in ovarian cancer, breast cancer, bronchial carcinoma and 1 more (3 cohorts), sponsored by AstraZeneca. Primary endpoints: Antitumor effect of durvalumab plus olaparib with or without bevacizumab and Safety and tolerability. Started Jun 2016; status: recruiting.
02
Drugs
durvalumabolaparibbevacizumab
03
Conditions
ovarian cancerbreast cancerbronchial carcinomagastric cancer (GC)
Beyond the preview
Go deeper on MOH_2018-12-17_004817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-17_004817.